Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_1212 |
Primary information | |
---|---|
B3PDB ID | b3pdb_1212 |
Peptide Name | P16 |
PEPTIDE SEQUENCE (1-letter) | VQILYK |
PEPTIDE SEQUENCE (3-letter) | NA |
N-terminal modification | N-terminal acetylation |
C-terminal modification | C-terminal amidation |
Chemical modification | NA |
Peptide Length | 6 |
Conformation | Linear |
Peptide Nature | NA |
Source/Origin of peptide | Chemically synthesized |
SMILES | NA |
Cell Line | Human brain endothelial cells (EA.hy926) |
In vitro CONCENTRATION | NA |
In vitro METHOD | Field-emission transmission electron microscope |
In vitro RESULT | A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a |
ANIMAL MODEL | NA |
In vivo CONCENTRATION | NA |
In vivo MODE OF DELIVERY | NA |
In vivo METHOD | NA |
In vivo RESULT | NA |
ACTION | Trojan peptides are capable of translo- cating the BBB, without affecting its interity. |
TRANSPORT TYPE | Translocation |
SUBCELLULAR LOCALISATION | NA |
COMBINATION | Comined with A3 pepide |
PHYSICAL CONDITION | Tauopathies |
RESPONSE | These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self |
RESULT | These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal |
LABEL | NA |
PMID | 32114026 |